532321 주식 개요 Zydus Lifesciences Limited는 인도, 미국 및 국제적으로 의약품의 연구, 개발, 생산, 마케팅, 유통 및 판매에 종사하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Zydus Lifesciences Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Zydus Lifesciences 과거 주가 현재 주가 ₹1,004.05 52주 최고치 ₹1,323.90 52주 최저치 ₹685.85 베타 0.47 1개월 변경 1.80% 3개월 변경 사항 -5.77% 1년 변경 사항 42.68% 3년 변화 127.08% 5년 변화 273.11% IPO 이후 변화 15,507.17%
최근 뉴스 및 업데이트
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations Jan 03
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5% Dec 19
Second quarter 2025 earnings: EPS misses analyst expectations Nov 13
Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Oct 31
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv Oct 23
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg Oct 18 더 많은 업데이트 보기
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations Jan 03
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5% Dec 19
Second quarter 2025 earnings: EPS misses analyst expectations Nov 13
Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Oct 31
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv Oct 23
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg Oct 18
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease Oct 15
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets Oct 10 Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg Oct 02
Price target increased by 10% to ₹1,170 Aug 12 Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets) Jul 23
Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava Jul 22
Upcoming dividend of ₹3.00 per share Jul 19
Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024 Jul 18
Full year 2024 earnings: EPS and revenues exceed analyst expectations Jul 16
Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg Jul 04
Dividend reduced to ₹3.00 May 24
Price target increased by 9.2% to ₹925 May 21
Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024 May 19
Full year 2024 earnings: EPS and revenues exceed analyst expectations May 18
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024 May 18
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis May 11
Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5% May 10
Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion. May 03 Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S
Insider recently sold ₹833k worth of stock Mar 26
Price target increased by 9.3% to ₹753 Feb 12
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 10 Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg Feb 09
Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India Jan 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg Jan 25
Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg Jan 19 Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg Dec 14
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 09
Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1 Oct 27
Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus Oct 21
Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America Oct 17
Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1% Sep 21
Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day Sep 16
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials Aug 25
Price target increased by 14% to ₹627 Aug 14
Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023 Aug 12
Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma. Aug 09
Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects Aug 04
Upcoming dividend of ₹6.00 per share at 1.0% yield Jul 21
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 19 Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg Jul 06 Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg
Price target increased by 7.6% to ₹536 May 21 Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 19
Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023 May 19
Zydus Group Reportedly Looks to Sell Cliantha Research May 05
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg Feb 18
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 05
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Febuxostat Tablets Jan 11
Zydus Lifesciences Limited Receives Two Final Approvals from the USFDA for Silodosin Capsules and Pregabalin Capsules Dec 11
Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration to Market Topiramate Extended-Release Capsules Dec 03
Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) entered into a Business Transfer Agreement to acquire Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma for approximately INR 470 million. Nov 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Famotidine Injection Nov 24
Zydus Lifesciences Limited Gets Exclusive Marketing Rights for CanAssist Breast Nov 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 16
Insufficient new directors Nov 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 13
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets Nov 10
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Acetaminophen Injection Oct 30
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Micafungin for Injection Oct 28
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Ketorolac Tromethamine Tablets Oct 23
Investor sentiment improved over the past week Oct 04
Zydus Lifesciences Limited Receives Final Approval from the USFDA for Lenalidomide Capsules 5 Mg, 10 Mg, 15 Mg and 25 Mg Sep 14
Zydus Lifesciences Limited Receives Final Approval and 180 Days Shared Exclusivity from the USFDA for Cariprazine Capsules Sep 13
Zydus Lifesciences Ltd. Achieves Positive Proof-of-Concept in its Phase 2 Clinical Study of ZYIL1, in Patients with CAPS Sep 08
Zydus Lifesciences Ltd. Announces Phase IV DREAM-CKD Trial to Generate Real World Evidence of Desidustat in Patients with Chronic Kidney Disease Induced Anemia Aug 30
Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022 Aug 11
Zydus Receives Final Approval from the USFDA for Ivermectin Cream Aug 06
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Bisoprolol Fumarate Tablets Jul 27
Upcoming dividend of ₹2.50 per share Jul 21 Zydus Lifesciences Limited to Report Q3, 2023 Results on Feb 14, 2023
Now 21% undervalued Jul 12
Zydus Lifesciences Ltd. Receives Final Approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets Jul 12
Zydus Lifesciences Limited Launches Molecule Sitagliptin in India Under the Brand Names Sitaglyn ® and Siglyn Jul 09 주주 수익률 532321 IN Pharmaceuticals IN 마켓 7D 2.9% -4.0% -4.5% 1Y 42.7% 29.0% 11.1%
전체 주주 수익률 보기
수익률 대 산업: 532321 지난 1년 동안 29 %를 반환한 Indian Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: 532321 지난 1년 동안 11.1 %를 반환한 Indian 시장을 초과했습니다.
가격 변동성 Is 532321's price volatile compared to industry and market? 532321 volatility 532321 Average Weekly Movement 3.1% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.1% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
안정적인 주가: 532321 지난 3개월 동안 Indian 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: 532321 의 주간 변동성 ( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 자이더스 라이프사이언스는 인도, 미국 및 국제적으로 의약품의 연구, 개발, 생산, 마케팅, 유통 및 판매에 종사하는 회사입니다. 이 회사는 두 가지 부문으로 운영됩니다: 제약 및 소비자 제품입니다. 제네릭, 브랜드 제네릭, 바이오시밀러 및 백신을 포함한 특수 제제, 활성 의약품 성분, 소비자 웰빙 제품, 동물 헬스케어 제품, 통증 관리, 신경학, 대사 장애 및 간 질환 치료 분야의 제품 등 완제품 인체용 제제를 제공합니다.
자세히 보기 Zydus Lifesciences Limited 기본 사항 요약 Zydus Lifesciences 의 수익과 매출은 시가총액과 어떻게 비교하나요? 532321 기본 통계 시가총액 ₹1.01t 수익(TTM ) ₹42.78b 수익(TTM ) ₹214.84b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 532321 손익 계산서(TTM ) 수익 ₹214.84b 수익 비용 ₹63.03b 총 이익 ₹151.81b 기타 비용 ₹109.03b 수익 ₹42.78b
주당 순이익(EPS) 42.51 총 마진 70.66% 순이익 마진 19.91% 부채/자본 비율 0.6%
532321 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/10 04:49 장 마감 주가 2025/01/10 00:00 수익 2024/09/30 연간 수익 2024/03/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Zydus Lifesciences Limited 69 애널리스트 중 29 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Nitin Bhasin Ambit Capital Sriraam Rathi Anand Rathi Shares and Stock Brokers Limited null null Anand Rathi Shares and Stock Brokers Limited
66 더 많은 분석가 보기 
